Axsome and Vertex Stock
Axsome stock ( NASDAQ:AXSM ) impressed investors this year, rising more than 80% through August . Investors applauded Axsome’s initial moves toward product launch. The biotech firm has given up a significant portion of its gain, yet it continues to defy the bear market.
Don’t worry if you missed out on that significant shift. Other stocks may benefit from the enthusiasm around new items. And one, in particular, is the ideal investment to purchase and keep. Vertex Pharmaceuticals stock ( NASDAQ:VRTX ) is the company I’m referring to. Let us investigate why.
Vertex Stock: Cystic Fibrosis Leadership
Vertex is well recognized as a pioneer in cystic fibrosis (CF) therapy . The firm offers four CF medicines, the most recent of which is generating blockbuster income. Last year, Trikafta produced more than $5.6 billion in product sales. This resulted in a $2.3 billion profit.
Vertex has the potential to maintain its top position until at least the late 2030s. This is thanks to Trikafta and a contender in phase 3 development. This contender has a good chance of beating Trikafta. Its dose, for example, is once a day rather than twice daily.
However, another therapy area might be driving Vertex’s stock ( NASDAQ:VRTX ) next round of market growth. Vertex is in the m...
Click here to read the full article on PressReach.com .Subscribe to the PressReach RSS feeds:
- Featured News RSS feed
- Investing News RSS feed
- Daily Press Releases RSS feed
- Trading Tips RSS feed
- Investing Videos RSS feed
Follow PressReach on Twitter
Follow PressReach on TikTok
Follow PressReach on Instagram
Subscribe to us on Youtube